CRLBF 6-K SEC Filing Analysis

Latest settled — T+20d

CRLBF ▼ -12.23% at T+20d

SHORT call ✓ call won +12.23% · α vs SPY +12.26% · entry $1.03 → $0.9040

Next anchor: T+60d in 8w

Last close $0.9500 (close Jun 8) · +7.77% from $1.03 entry (call sign-flipped)

Entry anchored
May 8, 2026
via day open

T+1d

-2.23%

call +2.23% · α +2.46%

$1.01

settled 4w ago

T+5d

-8.84%

call +8.84% · α +10.30%

$0.9390

settled 26d ago

T+20d

-12.23%

call +12.23% · α +12.26%

$0.9040

settled yesterday

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Cresco Labs reported Q1 2026 revenue of $151.3M, down 8.7% YoY from $165.8M, with a net loss of $17.0M (vs. $15.2M loss in Q1 2025). Revenue declined due to price compression in Illinois, Michigan excise tax disruption, and reduced California operations, partially offset by growth in Ohio and Massachusetts. The company is expanding via acquisitions (4 dispensaries for $14.7M in Q1, 9 more for ~$50M post-quarter) and was conditionally awarded a Texas medical license. The April 2026 federal rescheduling of medical cannabis to Schedule III could materially reduce tax burden under IRC Section 280E, but the financial impact is not yet estimable.

Actionable Insight

The revenue decline and cash burn are concerning, but the Schedule III rescheduling catalyst could dramatically improve future tax profile if 280E is eliminated for medical operations. Watch for DEA hearing outcomes on June 29 and any guidance on tax benefit quantification. The 9-dispensary acquisition (~$50M) and Texas license add growth optionality but near-term cash pressure persists.

Key Facts

Q1 2026 revenue of $151.3M, down 8.7% YoY from $165.8M
Net loss of $17.0M, compared to $15.2M loss in Q1 2025
Gross profit margin improved to 49.9% from 47.4% YoY
Adjusted EBITDA of $32.9M, down 9.2% from $36.2M in Q1 2025
Cash and cash equivalents fell to $32.3M from $57.9M at Dec 31, 2025
Operating cash flow was negative $5.6M vs. positive $30.5M in Q1 2025
Acquired 4 dispensaries in Q1 for $14.7M; post-quarter MSA for 9 more dispensaries for ~$50M
Conditionally awarded Texas Compassionate Use Program license on April 1, 2026
April 23, 2026 DOJ order reclassified medical cannabis to Schedule III; DEA hearings on broader rescheduling set for June 29, 2026
Senior Secured Term Loan of $325M at 12.5% interest, maturing August 2030; company in compliance with covenants

Financial Impact

Revenue declined $14.4M (-8.7%) YoY; net loss widened by $1.8M; operating cash flow swung from +$30.5M to -$5.6M; cash balance dropped $25.6M in the quarter

revenuenet incomeoperating cash flowcash and equivalents

Risk Factors

Continued revenue decline from price compression and competition in key states
Negative operating cash flow and declining cash reserves ($32.3M) could pressure liquidity
Uncertainty around timing and magnitude of tax benefits from Schedule III rescheduling
Integration risk from multiple dispensary acquisitions totaling ~$65M
High debt load ($325M term loan at 12.5% interest) with $30M minimum cash covenant

Market Snapshot

Exchange

OTC

Sector

Medicinal Chemicals & Botanical Products

Analyst Consensus

94% bullish (16 analysts)

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

Document	Accession Number
6-K Filing (Primary)	0001832928-26-000008
Document: q12026mda.htm	0001832928-26-000008
Document: q12026pressrelease.htm	0001832928-26-000008
Document: q12026form6-k.htm	0001832928-26-000008
Document: 0001832928-26-000008-index-headers.html	0001832928-26-000008
Document: 0001832928-26-000008-index.html	0001832928-26-000008
Document: 0001832928-26-000008.txt	0001832928-26-000008

US Market Status

Market Closed — Opens in 6h 54m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access